By utilizing a PICO framework, the Patient (NSCLC), Intervention (EGFR-TKIs plus Anti-VEGFR), Comparator (EGFR-TKIs), and Outcomes (PFS, OS, ORR), we conducted a meta-analysis to investigate whether the combination of EGFR-TKIs plus anti-VEGFR is associated with improved OS, PFS, and ORR compared to EGFR-TKIs alone in defined populations of advanced NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.